Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement

Shashank Chaturvedi ¹ * , Anurag Verma ² , Vikas Anand Saharan ³

Cited by CrossRef: 13

1- Yoon S, Kim H. First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations. IJMS. 2023;24(9):8389 [Crossref]

2- Yerram S, Joga R, Shende P, Varpe P, Bellapu K, Kumar S. Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence. Pharmaceutical Patent Analyst. 2023;12(5):219 [Crossref]

3- Wei D, Yang H, Zhang Y, Zhang X, Wang J, Wu X, Chang J. Nano-traditional Chinese medicine: a promising strategy and its recent advances. J Mater Chem B. 2022;10(16):2973 [Crossref]

4- Chaturvedi S, Rastogi V, Kumar M. An insight on nanofibers assisted localized delivery of anti-cancer drugs to breast for an effective breast cancer treatment. Journal of Drug Delivery Science and Technology. 2024;93:105447 [Crossref]

5- Harisa G, Sherif A, Alanazi F, Ali E, Omran G, Nasr F, Attia S, Alqahtani A. TPGS decorated NLC shift gefitinib from portal absorption into lymphatic delivery: Intracellular trafficking, biodistribution and bioavailability studies. Colloids and Surfaces B: Biointerfaces. 2023;223:113148 [Crossref]

6- Ramachandra D, Sudheer P. Self-micro Emulsifying Drug Delivery via Intestinal Lymphatics: A Lucrative Approach to Drug Targeting. PNT. 2023;11(3):238 [Crossref]

7- Cui J, Wen Z, Zhang W, Wu W. Recent Advances in Oral Peptide or Protein-Based Drug Liposomes. Pharmaceuticals. 2022;15(9):1072 [Crossref]

8- Sherif A, Harisa G, Shahba A, Alanazi F, Qamar W. Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer. Molecules. 2023;28(1):448 [Crossref]

9- MISHRA R, KULKARNI S, AHER A. ONE POT DEVELOPMENT OF LIPID-BASED QUERCETIN SPHERICAL AGGLOMERATES FOR BIOAVAILABILITY ENHANCEMENT: IN VITRO AND IN VIVO ASSESSMENTS. Int J App Pharm. 2023;:168 [Crossref]

10- Qiu C, Zhang J, Wu B, Xu C, Pang H, Tu Q, Lu Y, Guo Q, Xia F, Wang J. Advanced application of nanotechnology in active constituents of Traditional Chinese Medicines. J Nanobiotechnol. 2023;21(1) [Crossref]

11- Chaturvedi S, Garg A, Verma A. Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: An insight into the in-vitro, ex-vivo, in-situ and in-vivo study models. Journal of Drug Delivery Science and Technology. 2020;59:101899 [Crossref]

12- Handa M, Beg S, Shukla R, Barkat M, Choudhry H, Singh K. Recent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting. Journal of Controlled Release. 2021;340:48 [Crossref]

13- Liang Y, Liu Z, Wang P, Li Y, Wang R, Xie S. Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant. Journal of Controlled Release. 2021;336:396 [Crossref]

14- Sherif A, Harisa G, Alanazi F, Nasr F, Alqahtani A. PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer. IJN. 2022;Volume 17:3287 [Crossref]

15- Chaturvedi S, Garg A. A comprehensive review on novel delivery approaches for exemestane. Journal of Drug Delivery Science and Technology. 2022;75:103655 [Crossref]

16- Sherif A, Harisa G, Alanazi F. The Chimera of TPGS and Nanoscale Lipid Carriers as Lymphatic Drug Delivery Vehicles to Fight Metastatic Cancers. CDD. 2024;21(4):525 [Crossref]